Pharmacogenetics of lithium long-term treatment: Focus on initiation and adaptation mechanisms

Neuropsychobiology

Volumn 62, Issue 1, 2010, Pages 61-71

  Serretti, Alessandro ^a   Drago, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bipolar disorder; Gene; Lithium; Manic depression; Pharmacogenetics

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; FRUCTOSE BISPHOSPHATASE; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM SALT; METALLOTHIONEIN III; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOGLUCOMUTASE; PHOSPHOLIPASE C; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE D; RGS4 PROTEIN; RNA POLYMERASE; SEROTONIN TRANSPORTER; STRESS ACTIVATED PROTEIN KINASE; SYNAPSIN I; SYNAPSIN II; UNINDEXED DRUG; VALPROIC ACID; X BOX BINDING PROTEIN 1; LITHIUM DERIVATIVE; TRANQUILIZER;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; DRUG EFFICACY; DRUG EXPOSURE; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LONG TERM CARE; NEUROPROTECTION; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM; TIME;

ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; HUMANS; LITHIUM COMPOUNDS; TIME FACTORS;

EID: 77951941890     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314311     Document Type: Review

References (92)

1. Kessler RC, Rubinow DR, Holmes C, Abelson JM, Zhao S: The epidemiology of DSMIII- R bipolar I disorder in a general population survey. Psychol Med 1997; 27: 1079-1089.
2. Fajutrao LB, Locklear JC, Priaulx J, Heyes A: A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemol Ment Health 2009; 5: 3.
3. Hirschfeld RM, Calabrese JR, Weissman MM, Reed M, Davies MA, Frye MA, Keck PE Jr, Lewis L, McElroy SL, McNulty JP, Wagner KD: Screening for bipolar disorder in the community. J Clin Psychiatry 2003; 64: 53-59.
4. Gelenberg AJ, Hopkins HS: Report on efficacy of treatments for bipolar disorder. Psychopharmacol Bull 1993; 29: 447-456.
5. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM: Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217-222.
6. Manji HK, Potter WZ, Lenox RH: Signal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry 1995; 52: 531-543.
7. Hyman SE, Nestler EJ: Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996; 153: 151-162.
8. Quiroz JA, Gould TD, Manji HK: Molecular effects of lithium. Mol Interv 2004; 4: 259-272.
9. Seeds AM, York JD: Inositol polyphosphate kinases: regulators of nuclear function. Biochem Soc Symp 2007: 183-197.
10. Shears SB: Assessing the omnipotence of inositol hexakisphosphate. Cell Signal 2001; 13: 151-158.
11. Cockcroft S: Trafficking of phosphatidylinositol by phosphatidylinositol transfer proteins. Biochem Soc Symp 2007: 259-271.
12. Tolias KF, Cantley LC: Pathways for phosphoinositide synthesis. Chem Phys Lipids 1999; 98: 69-77.
13. Irvine RF, Schell MJ: Back in the water: the return of the inositol phosphates. Nat Rev Mol Cell Biol 2001; 2: 327-338.
14. Resnick AC, Saiardi A: Inositol polyphosphate multikinase: metabolic architect of nuclear inositides. Front Biosci 2008; 13: 856-866.
15. Berridge MJ, Downes CP, Hanley MR: Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989; 59: 411-419.
16. Willmroth F, Drieling T, Lamla U, Marcushen M, Wark HJ, van Calker D: Sodiummyo- inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers. Int J Neuropsychopharmacol 2007; 10: 63-71.
17. Ikonomov OC, Manji HK: Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Am J Psychiatry 1999; 156: 1506-1514.
18. Kofman O, Belmaker RH: Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry 1993; 34: 839-852.
19. Fauroux CM, Freeman S: Inhibitors of inositol monophosphatase. J Enzyme Inhib 1999; 14: 97-108.
20. Phiel CJ, Klein PS: Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001; 41: 789-813.
21. Harwood AJ: Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol Psychiatry 2005; 10: 117-126.
22. Harwood AJ, Agam G: Search for a common mechanism of mood stabilizers. Biochem Pharmacol 2003; 66: 179-189.
23. Agam G, Shamir A, Shaltiel G, Greenberg ML: Myo-inositol-1-phosphate (MIP) synthase: a possible new target for antibipolar drugs. Bipolar Disord 2002; 4(suppl 1):15-20.
24. Lenox RH, Hahn CG: Overview of the mechanism of action of lithium in the brain: fiftyyear update. J Clin Psychiatry 2000; 61(suppl 9):5-15.
25. Lenox RH, Wang L: Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol Psychiatry 2003; 8: 135-144.
26. Silverstone PH, McGrath BM, Kim H: Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord 2005; 7: 1-10.
27. Dimitrova A, Milanova V, Krastev S, Nikolov I, Toncheva D, Owen MJ, Kirov G: Association study of myo-inositol monophosphatase 2 (IMPA2) polymorphisms with bipolar affective disorder and response to lithium treatment. Pharmacogenomics J 2005; 5: 35-41.
28. Sjoholt G, Ebstein RP, Lie RT, Berle JO, Mallet J, Deleuze JF, Levinson DF, Laurent C, Mujahed M, Bannoura I, Murad I, Molven A, Steen VM: Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder. Mol Psychiatry 2004; 9: 621-629.
29. Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E: A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 2004; 368: 123-126. (Pubitemid 39194855)
30. Benedetti F, Bernasconi A, Lorenzi C, Pontiggia A, Serretti A, Colombo C, Smeraldi E: A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 2004; 355: 37-40. (Pubitemid 38077179)
31. Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C, Smeraldi E: Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 2005; 376: 51-55.
32. Michelon L, Meira-Lima I, Cordeiro Q, Miguita K, Breen G, Collier D, Vallada H: Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta gene variants and retrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett 2006; 403: 288-293.
33. Szczepankiewicz A, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Dmitrzak-Weglarz M, Czerski PM, Hauser J: Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients. World J Biol Psychiatry 2006; 7: 158-161.
34. Szczepankiewicz A, Skibinska M, Hauser J, Slopien A, Leszczynska- Rodziewicz A, Kapelski P, Dmitrzak-Weglarz M, Czerski PM, Rybakowski JK: Association analysis of the GSK-3beta T-50C gene polymorphism with schizophrenia and bipolar disorder. Neuropsychobiology 2006; 53: 51-56. (Pubitemid 43254178)
35. Seelan RS, Khalyfa A, Lakshmanan J, Casanova MF, Parthasarathy RN: Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells. Neuroscience 2008; 151: 1184-1197.
36. Manji HK, Lenox RH: Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 1994; 16: 11-28.
37. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258: 607-614.
38. Stabel S, Parker PJ: Protein kinase C. Pharmacol Ther 1991; 51: 71-95.
39. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G: Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry 1999; 60(suppl 2):27-39; discussion 40-41, 113-116.
40. Manji HK, Etcheberrigaray R, Chen G, Olds JL: Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J Neurochem 1993; 61: 2303-2310.
41. Arnsten AF: Ameliorating prefrontal cortical dysfunction in mental illness: inhibition of phosphotidyl inositol-protein kinase C signaling. Psychopharmacology (Berl) 2009; 202: 445-455.
42. Lenox RH, McNamara RK, Watterson JM, Watson DG: Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 1996; 57(suppl 13):23-31; discussion 32-33.
43. Gutkind JS: The pathways connecting G protein- coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 1998; 273: 1839-1842.
44. Plant KE, Anderson E, Simecek N, Brown R, Forster S, Spinks J, Toms N, Gibson GG, Lyon J, Plant N: The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol 2009; 235: 124-134.
45. Chetcuti A, Adams LJ, Mitchell PB, Schofield PR: Microarray gene expression profiling of mouse brain mRNA in a model of lithium treatment. Psychiatr Genet 2008; 18: 64-72.
46. Ikonomov OC, Petrov T, Soden K, Shisheva A, Manji HK: Lithium treatment in ovo: effects on embryonic heart rate, natural death of ciliary ganglion neurons, and brain expression of a highly conserved chicken homolog of human MTG8/ETO. Brain Res Dev Brain Res 2000; 123: 13-24.
47. Manji HK, Moore GJ, Chen G: Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manicdepressive illness. Biol Psychiatry 2000; 48: 740-754.
48. Chen G, Huang LD, Jiang YM, Manji HK: The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72: 1327-1330.
49. Manji HK, Moore GJ, Chen G: Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 1999; 46: 929-940.
50. Rajkowska G, Halaris A, Selemon LD: Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001; 49: 741-752.
51. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK: Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000; 75: 1729-1734.
52. Chen RW, Chuang DM: Long-term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274: 6039-6042.
53. Lu R, Song L, Jope RS: Lithium attenuates p53 levels in human neuroblastoma SHSY5Y cells. Neuroreport 1999; 10: 1123-1125.
54. Segal RA, Greenberg ME: Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 1996; 19: 463-489.
55. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME: Ca 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 1998; 20: 709-726.
56. Corena-McLeod MDP, Oliveros A, Charlesworth C, Madden B, Liang YQ, Boules M, Shaw A, Williams K, Richelson E: Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res 2008; 1233: 8-19.
57. Jovanovic JN, Czernik AJ, Fienberg AA, Greengard P, Sihra TS: Synapsins as mediators of BDNF-enhanced neurotransmitter release. Nat Neurosci 2000; 3: 323-329.
58. Rybakowski JK, Suwalska A, Skibinska M, Szczepankiewicz A, Leszczynska-Rodziewicz A, Permoda A, Czerski PM, Hauser J: Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005; 38: 166-170. (Pubitemid 41059223)
59. Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S, Kunugi H, Koyama T: A possible association between the -116C/ G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol 2006; 9: 83-88.
60. Rybakowski JK, Suwalska A, Skibinska M, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J: Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:820-823.
61. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Szczepankiewicz A, Hauser J: Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 2008; 9: 1595-1603.
62. Mamdani F, Alda M, Grof P, Young LT, Rouleau G, Turecki G: Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:500-504.
63. Riccio A, Ahn S, Davenport CM, Blendy JA, Ginty DD: Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 1999; 286: 2358-2361.
64. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286: 1358-1362.
65. Ruhe HG, Mason NS, Schene AH: Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a metaanalysis of monoamine depletion studies. Mol Psychiatry 2007; 12: 331-359.
66. Harro J, Oreland L: Depression as a spreading adjustment disorder of monoaminergic neurons: a case for primary implication of the locus coeruleus. Brain Res Brain Res Rev 2001; 38: 79-128.
67. Millan MJ: The role of monoamines in the actions of established and 'novel' antidepressant agents: a critical review. Eur J Pharmacol 2004; 500: 371-384.
68. Serretti A, Artioli P: From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology (Berl) 2004; 174: 490-503.
69. Serretti A, Lorenzi C, Lilli R, Smeraldi E: Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res 2000; 34: 89-98. (Pubitemid 30176115)
70. Serretti A, Lilli R, Lorenzi C, Franchini L, Di Bella D, Catalano M, Smeraldi E: Dopamine receptor D 2 and D 4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res 1999; 87: 7-19.
71. Serretti A, Lilli R, Lorenzi C, Franchini L, Smeraldi E: Dopamine receptor D 3 gene and response to lithium prophylaxis in mood disorders. Int J Neuropsychopharmcol 1998; 1: 125-129. (Pubitemid 128538373)
72. Serretti A, Lorenzi C, Lilli R, Mandelli L, Pirovano A, Smeraldi E: Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants. Am J Med Genet 2002; 114: 370-379.
73. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, Slopien A, Czerski PM, Leszczynska- Rodziewicz A, Hauser J: Association studies of 5-HT2A and 5-HT2C serotonin receptor gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacol Rep 2005; 57: 761-765.
74. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E: Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 2001; 1: 71-77.
75. Serretti A, Malitas PN, Mandelli L, Lorenzi C, Ploia C, Alevizos B, Nikolaou C, Boufidou F, Christodoulou GN, Smeraldi E: Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics J 2004; 4: 267-273.
76. Serretti A, Lilli R, Lorenzi C, Gasperini M, Smeraldi E: Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res 1999; 33: 371-377.
77. Gray NA, Du J, Falke CS, Yuan P, Manji HK: Lithium regulates total and synaptic expression of the AMPA glutamate receptor GluR2 in vitro and in vivo. Ann NY Acad Sci 2003; 1003: 402-404.
78. Riederer P, Hoyer S: From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm 2006; 113: 1671-1677.
79. Kuiper MA, Teerlink T, Visser JJ, Bergmans PL, Scheltens P, Wolters EC: L -glutamate, L - arginine and L -citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm 2000; 107: 183-189.
80. Sodhi M, Wood KH, Meador-Woodruff J: Role of glutamate in schizophrenia: integrating excitatory avenues of research. Expert Rev Neurother 2008; 8: 1389-1406.
81. Ferraro F, Ma XM, Sobota JA, Eipper BA, Mains RE: Kalirin/Trio Rho guanine nucleotide exchange factors regulate a novel step in secretory granule maturation. Mol Biol Cell 2007; 18: 4813-4825.
82. Shimshoni JA, Dalton EC, Jenkins A, Eyal S, Ewan K, Williams RS, Pessah N, Yagen B, Harwood AJ, Bialer M: The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Mol Pharmacol 2007; 71: 884-892.
83. Williams RS, Cheng L, Mudge AW, Harwood AJ: A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292-295.
84. Martinez A, Perez DI: GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 2008; 15: 181-191.
85. Wada A, Yokoo H, Yanagita T, Kobayashi H: Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci 2005; 99: 307-321.
86. Bauer M, Alda M, Priller J, Young LT: Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 2003; 36(suppl 3):S250-S254.
87. Serretti A, Kato M, Kennedy JL: Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 2008; 8: 90-100.
88. Mamdani F, Sequeira A, Alda M, Grof P, Rouleau G, Turecki G: No association between the PREP gene and lithium responsive bipolar disorder. BMC Psychiatry 2007; 7: 9.
89. Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S, Suzuki T, Iwata N, Ozaki N, Kato T, Kunugi H, Koyama T: Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatr Genet 2006; 16: 49-50.
90. Rybakowski JK, Suwalska A, Czerski PM, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J: Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep 2005; 57: 124-127.
91. Washizuka S, Ikeda A, Kato N, Kato T: Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. Int J Neuropsychopharmacol 2003; 6: 421-424.
92. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK: The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998; 8: 259-268.